Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun052015	Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases Proof-of-Concept Data in Well-Established Model of Type 1 Diabetes Presented Today at the 75th Scientific Sessions of the American Diabetes Association Read All »	View HTML Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases 23.7 KB
Toggle SummaryMay272015	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO , May 27, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the closing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 147.1 KB
Toggle SummaryMay202015	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , May 20, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 148.1 KB
Toggle SummaryMay182015	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , May 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that it has commenced an underwritten public Read All »	View HTML Fate Therapeutics Announces Proposed Public Offering of Common Stock 20.8 KB
Toggle SummaryMay072015	Fate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional Data from Ongoing Phase 2 PUMA Study of PROHEMA® Continue to Demonstrate Acceleration of, and Increased Incidence of Early, Neutrophil Read All »	View HTML Fate Therapeutics Reports First Quarter 2015 Financial Results 30.9 KB
Toggle SummaryMay062015	Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies Alliance Utilizes Fate's Hematopoietic Cell Programming Platform to Identify Small Molecule Modulators for Juno's Leading Genetically-Engineered T Cell Immunotherapies Read All »	View HTML Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies 27.1 KB
Toggle SummaryMay042015	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 10.8 KB
Toggle SummaryApr292015	Fate Therapeutics to Present at Deutsche Bank 40th Annual Health Care Conference SAN DIEGO, April 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at Deutsche Bank 40th Annual Health Care Conference 10.5 KB
Toggle SummaryApr082015	Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference SAN DIEGO, April 8, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at 14th Annual Needham Healthcare Conference 10.5 KB
Toggle SummaryMar182015	Fate Therapeutics to Present at the Regen Med Investor Day SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President and Read All »	View HTML Fate Therapeutics to Present at the Regen Med Investor Day 10.5 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.